⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376367 | 0.67 | — | — | |
| SCHEMBL38257 | 0.61 | — | — | |
| Ethyne SCHEMBL1051990 | 0.58 | — | — | |
| SCHEMBL33362 | 0.55 | — | — | |
| SCHEMBL6151482 | 0.55 | — | — | |
| SCHEMBL1171363 | 0.55 | — | — | |
| SCHEMBL237675 | 0.55 | — | — | |
| SCHEMBL471774 | 0.50 | — | — | |
| SCHEMBL679120 | 0.50 | — | — | |
| SCHEMBL477843 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117597139-A | Uridine phosphorylase inhibitors for preventing or treating drug-induced pulmonary dysfunction | 托斯克公司 | 2024-02-23 | — | — | CN | claimed |
| EP-4301398-A1 | URIDINE PHOSPHORYLASE INHIBITORS TO PREVENT OR TREAT DRUG-INDUCED PULMONARY DYSFUNCTION | Tosk, Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| US-20230255971-A1 | Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver Conditions | TOSK, INC. | 2023-08-17 | — | — | US | claimed |
| EP-4178581-A1 | URIDINE PHOSPHORYLASE INHIBITORS TO TREAT OR PREVENT PULMONARY DISEASE | Tosk, Inc. (US) | 2023-05-17 | — | — | EP | claimed |
| CN-116096422-A | Uridine phosphorylase inhibitors for treating or preventing pulmonary diseases | 托斯克公司 | 2023-05-09 | — | — | CN | claimed |
| CN-114450009-A | Uridine Phosphorylase (UPASE) inhibitors for the treatment of liver diseases | 托斯克公司 | 2022-05-06 | — | — | CN | claimed |
| EP-3986409-A1 | URIDINE PHOSPHORYLASE (UPASE) INHIBITORS FOR TREATMENT OF LIVER CONDITIONS | Tosk, Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| WO-2022010778-A1 | URIDINE PHOSPHORYLASE INHIBITORS TO TREAT OR PREVENT PULMONARY DISEASE | TOSK, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| US-20220008422-A1 | Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease | TOSK, INC. | 2022-01-13 | — | — | US | claimed |
| US-20210236530-A1 | Methods and Compositions for Treating Mucositis | TOSK, INC. | 2021-08-05 | — | — | US | claimed |
| EP-0882058-A1 | NOVEL NUCLEOSIDE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | CHONG KUN DANG CORP (KR) | 1998-12-09 | — | — | EP | claimed |
| US-5679652-A | THERAPY FOR CANCER, INFECTIONS | SCHOTT HERBERT (DE) | 1997-10-21 | — | — | US | claimed |
| WO-1997016456-A1 | NOVEL NUCLEOSIDE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | CHONG KUN DANG CORP. (KR) | 1997-05-09 | — | — | WO | claimed |
| EP-0642527-B1 | AMPHIPHILIC NUCLEOSIDE PHOSPHATE ANALOGS | SCHOTT HERBERT (DE) | 1996-01-10 | — | — | EP | claimed |
| US-5359067-A | Process for the preparation of 5-substituted cytosines and other 4,5-disubstituted pyrimidin-2(1H)-ones, and intermediates arising in the course of this | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-25 | — | — | US | claimed |
| US-5120849-A | Reacting cyclic imidoether with aminoalcohol | BASF AKTIENGESELLSCHAFT (DE) | 1992-06-09 | — | — | US | claimed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | claimed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
| EP-0229642-B1 | AZOLE DERIVATIVES, FUNGICIDES AND GROWTH REGULATORS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1990-07-11 | — | — | EP | claimed |
| US-4605659-A | HERPES; HEPATITUS | SYNTEX (U.S.A.) INC. (US) | 1986-08-12 | — | — | US | claimed |